Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 4:10 PM ET
Seres Therapeutics Inc (MCRB) Stock Chart
Seres Therapeutics (MCRB) has a latest price of $1.41 on Nov 17, 2026, 95.3% below its 52-week high of $29.98. Its price fell 91.5% over the past 12 months. The month-end price fell 99.2% over the 10 years through Oct 2026, a compound annual decline of 38.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $566.20 in Sep 2020 and its lowest $1.77 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart MCRB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for MCRB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 69.9%, and over 6 months it fell 81.0%. The month-end price fell 94.2% over the 3 years through Oct 2026, a compound annual decline of 61.3%.
| Period | Change |
|---|---|
| 1 month | -41.7% |
| 3 months | -69.9% |
| 6 months | -81.0% |
| 12 months | -91.5% |
| 12 months, with dividends | -91.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -94.2% | -61.3% |
| 5 years | -98.5% | -57.1% |
| 10 years | -99.2% | -38.1% |
Price by Year
Its best calendar year was 2020, when the price rose 610.1%, and its weakest was 2023, when it fell 75.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.77 | -88.1% |
| 2025 | $14.88 | -10.5% |
| 2024 | $16.62 | -40.6% |
| 2023 | $28.00 | -75.0% |
| 2022 | $112.00 | -32.8% |
| 2021 | $166.60 | -66.0% |
| 2020 | $490.00 | +610.1% |
| 2019 | $69.00 | -23.7% |
| 2018 | $90.40 | -55.4% |
| 2017 | $202.80 | +2.4% |
Trading Range
The price is 49.5% below its 50-day average of $2.79 and 77.6% below its 200-day average of $6.29.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.41 | |
| 52-week high | $29.98 | -95.3% |
| 52-week low | $1.30 | +8.5% |
| 50-day average | $2.79 | -49.5% |
| 200-day average | $6.29 | -77.6% |
Price Risk
Over 3 years, its largest fall from a peak was 95.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.43 |
| Largest fall, 1 year | -95.1% |
| Largest fall, 3 years | -95.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About MCRB
What is MCRB's 1-year price change?
Seres Therapeutics's price fell 91.5% over the past 12 months. With dividends included, the 12-month total return was -91.5%.
What is MCRB's 5-year price change?
Seres Therapeutics's month-end price fell 98.5% over the 5 years through Oct 2026, a compound annual decline of 57.1%. These figures leave out dividends.
What is MCRB's 52-week high and low?
Seres Therapeutics's 52-week high is $29.98 and its 52-week low is $1.30. Its latest price of $1.41 on Nov 17, 2026 is 95.3% below the high.
What is MCRB's beta?
Seres Therapeutics's 1-year beta against the S&P 500 is 1.43, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 95.1%.
Is the MCRB chart free?
Yes. Advanced Charting for MCRB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
MCRB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors